What pharmacologic options are recommended for an adult with inhalant (air‑duster) dependence experiencing cravings?

No FDA-Approved Medications for Inhalant Cravings

There are currently no FDA-approved pharmacologic treatments for inhalant use disorder, including air-duster dependence and cravings 1, 2. The evidence base for medication management of inhalant dependence is extremely limited, consisting primarily of small case reports rather than controlled trials.

Limited Pharmacologic Evidence

While no medications can be formally recommended for primary care use, several agents have shown preliminary signals in case reports and small studies 2:

• Aripiprazole demonstrated reductions in sustained inhalant use in small clinical studies
• Baclofen, naltrexone, and lamotrigine showed varying degrees of success in promoting abstinence in individual case reports
• These findings are based on extremely limited data and cannot support routine clinical recommendations

The certainty of evidence for any pharmacologic intervention is very low to low 2, making it impossible to recommend specific medications with confidence for morbidity or mortality reduction.

Recommended Clinical Approach

Behavioral therapies represent the primary evidence-based treatment modality for inhalant dependence 1, 2. The treatment algorithm should proceed as follows:

Immediate Management

1. Medical stabilization if acute intoxication is present (ABCDE approach: airway, breathing, circulation, disability, exposure assessment)
2. Decontamination if recent exposure occurred
3. Screen for multisystem toxicity affecting cardiac, neurologic, hepatic, renal, and pulmonary systems 3

Ongoing Treatment Strategy

Refer to behavioral therapy programs as the primary intervention:

• Cognitive behavioral therapy (CBT)-based brief interventions have demonstrated reduction in volatile substance use 2
• Family therapy shows benefit, particularly in younger patients
• Residential programs with multifaceted approaches (combining psychosocial support, cultural elements, and structured environments) demonstrate the highest success rates 2

Psychiatric Comorbidity Management

Screen and treat co-occurring psychiatric disorders aggressively 1:

• Anxiety disorders, depression, bipolar disorder, and PTSD are significantly more common in patients with substance use disorders
• Treat these conditions with standard evidence-based pharmacotherapy for the specific psychiatric diagnosis
• This may indirectly reduce substance use by addressing underlying drivers of inhalant misuse

Critical Pitfalls

Do not prescribe benzodiazepines for anxiety in this population—they carry high risk of dependence and complicate substance use treatment 1. If anxiety treatment is needed, consider SSRIs or other non-addictive alternatives.

Avoid stimulant medications even if ADHD is suspected, as the evidence for pharmacologic management of stimulant-like substance dependence (which shares some neurobiological features with inhalants) shows no benefit in primary care settings 1.

When to Refer

Refer to addiction medicine specialists when:

• Patient has failed behavioral interventions
• Severe psychiatric comorbidity is present requiring specialized management
• Patient requests or would benefit from residential treatment programs
• Medical complications from chronic inhalant use require subspecialty care 2, 3

The harsh reality is that inhalant use disorder remains one of the most neglected forms of substance abuse with minimal pharmacologic treatment options 2, 3. Your primary therapeutic tool is connecting patients to intensive behavioral interventions and managing psychiatric comorbidities that may be driving the substance use.